Lekha Mikkilineni is an Oncology physician affiliated with Palo Alto University. OpenAlex indexes 115 publications with 2,634 citations (h-index 18).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
300 Pasteur Dr
Stanford, CA 943052200
Telephone
650-723-4000Provider last certified this registry record 15 Apr 2024.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Global Services, LLCProgram year20252 payments
- Celgene CorporationProgram year20251 payment
- Kite Pharma, Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
28.6%Short-acting sulfonamides15.5%Sulfamethoxazole-Trimethoprim100%Part D≥21 patientsFluoroquinolone Antibacterial7.3%Levofloxacin100%Part D≥13 patients+ 1 more class in this area
Dermatology
27.3%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor27.3%Acyclovir100%Part D≥24 patientsNervous system
12.7%Benzodiazepine7.8%Lorazepam100%Part D≥15 patientsPhenothiazine4.9%Prochlorperazine Maleate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology
2025 - Managing IEC-associated enterocolitis following CAR-T therapy in multiple myeloma
Blood Cancer Journal
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Tait Shanafelt, MD
Palo Alto University
Victor Froelicher, MD
Palo Alto University
Kimford Meador, MD
Palo Alto University
Michael Marmor, MD
Palo Alto University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”